(Press-News.org) A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial conducted in the first half of 2021 and co-led by researchers at Weill Cornell Medicine and NewYork-Presbyterian.
The trial, described in a paper appearing online Apr. 18 in Annals of Internal Medicine, enrolled more than 800 non-hospitalized patients with COVID-19 at high-risk of progression of the disease in the United States and five other countries. Those who were randomly assigned to be treated with the combination of the two antibodies, amubarvimab and romlusevimab, had only a 2.3 percent rate of progression to hospitalization and/or death, compared to 10.7 percent in the placebo group, a highly significant difference. The treatment also appeared safe.
“This was a randomized, blinded, placebo-controlled clinical trial—the gold standard as we call it—that was conducted as a large international collaboration in the midst of a global pandemic, and demonstrated strong effectiveness and safety for this treatment,” said study co-first author Dr. Teresa Evering, an assistant professor of medicine in the Division of Infectious Diseases at Weill Cornell Medicine and an infectious disease specialist at NewYork-Presbyterian/Weill Cornell Medical Center.
The study, which is part of the ACTIV-2 Study of Outpatient Monoclonal Antibodies and Other Therapies was also co-led by researchers at the University of California-San Diego, The Geffen School of Medicine at UCLA, and the Lundquist Institute at Harbor-UCLA Medical Center. ACTIV-2 is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and is part of NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership.
The combination monoclonal antibody treatment was jointly developed by the China and U.S.-based company Brii Biosciences, Tsinghua University and the Third People’s Hospital of Shenzhen. The two antibodies, which are based on antibodies originally isolated from recovering COVID-19 patients, hobble SARS-CoV-2’s ability to spread by targeting two non-overlapping structures in the virus’s receptor binding domain.
The trial enrolled non-hospitalized patients with early, mild to moderate COVID-19 who were considered at high risk of progression to severe COVID-19. The participating medical centers were in Argentina, Brazil, Mexico, the Philippines, South Africa and the United States. Enrollment took place during January to July of 2021, and the final analysis covered 807 patients, the vast majority of whom were from the United States, South Africa or Argentina.
Although the treatment and placebo groups were roughly equal in number (397 and 410), 44 of the 53 total hospitalizations and/or deaths occurred in the placebo group, compared with only 9 in the treatment group—a 79 percent reduction in risk for the latter. The analysis also found that the antibody treatment worked about as well for patients enrolled 6 to 10 days after symptom onset as it did for patients enrolled earlier. It also appeared to be effective against the delta variant of SARS-CoV-2, which emerged and spread worldwide during the study. Moreover, the safety analysis found that reports of treatment-related side effects were significantly lower in the treatment group compared to the placebo group, suggesting that the treatment was safe.
The amubarvimab-plus-romlusevimab treatment was granted approval by the National Medical Products Administration (NMPA) of China in late 2021 and was later used in hundreds of Chinese hospitals. It was found to be effective in lab tests against early omicron variants. However, it was never approved for use in the U.S., and like other anti-SARS-CoV-2 antibody treatments, it may have reduced efficacy for currently circulating variants. Brii Biosciences announced last month that it was shelving production of the treatment.
“We were honored to play a role in a study that clearly demonstrated the safety and efficacy of a monoclonal antibody combination therapy in reducing hospitalizations and deaths among those with mild to moderate COVID-19 at high risk for clinical progression, prior to the emergence of omicron variants,” Dr. Evering said.
END
Antibody combination provided strong protection against severe COVID-19 in large international trial
2023-04-19
ELSE PRESS RELEASES FROM THIS DATE:
Accredited geriatric emergency departments continue to grow within VA hospitals
2023-04-19
WASHINGTON, D.C.—April 19, 2023—The U.S. Department of Veterans Affairs (VA), the largest integrated healthcare system in the nation, today announced that 60 of its 111 emergency departments have earned Geriatric Emergency Department Accreditation (GEDA) from the American College of Emergency Physicians (ACEP). Another 11 departments are on track to earn the designation in coming months and the VA has plans to expand the program to the majority of its hospitals over the next three years.
Geriatric emergency departments provide specialized care to older veterans and their families during and after a ...
NASA selects NAU researcher for international mission to Martian moons
2023-04-19
A planetary scientist at NAU is part of a Japanese Aerospace Exploration Agency (JAXA) mission to travel to Mars and survey the planet’s two moons, including collecting a sample from one and returning it to Earth.
Christopher Edwards, an associate professor in the Department of Astronomy and Planetary Science, received a six-year, $650,000 grant for the Martian Moons eXploration (MMX) mission awarded by NASA. This goal is to send an uncrewed spacecraft to Mars’ two moons, Phobos and Deimos, to gather information about them. It also will collect surface material from Phobos, a first-of-its-kind attempt.
Edwards, ...
Warm-up time corrects creativity power imbalance
2023-04-19
ITHACA, N.Y. – Power often boosts an employee’s creativity because being powerful liberates the individual from constraints, such as worrying that their ideas will be rejected. However, new research shows that employees who are not in positions of power can become more creative when given time to “warm up” to a task by engaging in the creative task more than once.
“This is important because when people with more power are able to express their creative ideas more than those with less power, ...
Study finds extreme mortality rate in Central African Republic
2023-04-19
A new study by public health researchers presents stark evidence that the Central African Republic (CAR) is experiencing a severe health and humanitarian emergency, with what is likely the highest measured nationwide mortality rate in the world, a rate four times higher than a 2010 United Nations estimate. The present crisis is linked to the arrival of COVID and its associated disruptions, as well as human rights abuses by the Wagner Group, a Russian paramilitary organization, which seeks to regain national territory after a decades-long hold by rebel groups.
The findings are based on a nationwide mortality survey and appear in the peer-reviewed journal Conflict ...
Georgetown psychologists map the psyche of extreme altruists
2023-04-19
Although many people admire the actions of people who engage in acts of extraordinary altruism, like altruistic organ donors, bone marrow donors, and heroes who rescue people from fires or accidents, they are also often mystified at what motivates these altruists to act.
A new paper from a team of Georgetown researchers aims to answer this question by mapping out the psychological profiles of a range of extreme real-world altruists, like heroic rescuers, humanitarian aid workers, and people who donate organs or bone marrow to strangers at no benefit to themselves.
“After evaluating more than 300 extreme ...
STEMM opportunity alliance announces more than 100 partners
2023-04-19
Washington, D.C. – The STEMM Opportunity Alliance (SOA), a national effort galvanizing stakeholders to achieve equity and excellence in science, technology, engineering, mathematics, and medicine (STEMM) by 2050, announced a milestone of more than 100 partners since its launch at the White House Summit on STEMM Equity and Excellence in December 2022.
Some highlights from SOA’s newest partners and their commitments include:
Johnson & Johnson will continue growing multiple projects ...
Model that uses machine learning methods and patient data at hospital arrival predicts strokes more accurately than current system
2023-04-19
Stroke is among the most dangerous and commonly misdiagnosed medical conditions. Black and Hispanic people, women, older people on Medicare, and people in rural areas are less likely to be diagnosed in time for treatment to be effective. In a new study, researchers used machine learning methods and data available when patients enter the hospital to develop a model that predicts strokes with more accuracy than current models.
The study, by researchers at Carnegie Mellon University (CMU), Florida International University (FIU), and Santa Clara University (SCU), appears in the Journal of Medical Internet ...
Organic beekeeping rivals conventional methods for bee health, productivity
2023-04-19
UNIVERSITY PARK, Pa. — Honey bee colonies managed using organic methods were as healthy and productive as those managed in conventional systems, while avoiding the use of synthetic pesticides to control pests and pathogens inside the hive, according to newly published research led by Penn State entomologists.
The researchers said they believe that their study, which compared the performance of honey bees under three types of management systems, is the first to show that organic beekeeping management is sustainable and supports high honey-bee survival and honey production.
The methods beekeepers use to manage honey ...
Tribal water rights underutilized in U.S. West
2023-04-19
A new North Carolina State University study shows that Indigenous groups in the western United States are – for various reasons – having difficulty turning water they have a legal right to, under water rights settlements, into actual water that can generate revenue through leases to other groups or through direct uses such as agriculture.
Western tribal water rights are a longstanding, yet underpublicized, component of a large and seemingly intractable problem: how to satisfy all water-rights holders when available ...
Stronger paper bags, reused repeatedly then recycled for biofuel could be future
2023-04-19
UNIVERSITY PARK, Pa. — As the world searches for ways to reduce the use of plastics such as single-use plastic bags, a novel study by Penn State researchers demonstrates a process to make paper bags stronger — especially when they get wet — to make them a more viable alternative.
The study suggests a process for creating paper bags durable enough to be used multiple times and then broken down chemically by an alkaline treatment to be used as a source for biofuel production, according to researcher Daniel Ciolkosz, associate ...